Abstract
CD9 is a crucial regulator of cell adhesion in the immune system and plays important physiological roles in hematopoiesis, blood coagulation or viral and bacterial infections. It is involved in the transendothelial migration of leukocytes which might also be hijacked by cancer cells during their invasion and metastasis. CD9 is found at the cell surface and the membrane of exosomes affecting cancer progression and therapy resistance. High expression of CD9 is mostly associated with good patients outcome, with a few exceptions. Discordant findings have been reported for breast, ovarian, melanoma, pancreatic and esophageal cancer, which might be related to using different antibodies or inherent cancer heterogeneity. According to in vitro and in vivo studies, tetraspanin CD9 is not clearly associated with either tumor suppression or promotion. Further mechanistic experiments will elucidate the role of CD9 in particular cancer types and specific conditions.
1 Introduction
Tetraspanin CD9, also known as TSPAN29 or motility-related protein 1, is a member of the transmembrane 4 superfamily proteins, which are characterized by four transmembrane domains, two extracellular loops, and short intracellular N-and C-terminal tails (Figure 1A) (1, 2). Like other tetraspanins, CD9 can undergo palmitoylation on each of its membrane-proximal cysteines which affects its interactions with other partners (3). Tetraspanins generally form tetraspanin-enriched microdomains (TEMs) in cell membranes. Within these domains, they interact with various transmembrane and intracellular partners, including other tetraspanins, integrins, proteases, immunoglobulins, and intracellular signaling proteins (4). Therefore, the biological effects of CD9 depend on these dynamic interactions within the context of TEMs (1, 24). Recently, a “concatenation model” for forming CD9/EWI-F assemblies has been suggested, which may explain the occurrence of these TEMs (25). Besides tetraspanins (e.g. CD63, CD81, CD151 and TSPAN4), CD9 interacts with numerous single-span transmembrane proteins, such as integrins (e.g. CD49c/ITGA3 and CD29 (1, 26), immunoglobulin superfamily proteins (e.g. EWI-F/PTGFRN and EWI-2/IGSF8) (1, 27), heparin-binding EGF-like growth factor (28), and metalloprotease ADAM17 (A Disintegrin And Metalloproteinase 17) (29). Previously, CD9 has also shown the ability to interact with other proteins such as CD19, CD46 and CD117 (30–32).
Figure 1
An equally important role is played by the interaction of tetraspanins with intracellular signaling molecules, although significantly fewer of them have been identified compared to transmembrane partners (4). In the context of CD9, these are mainly interactions with small GTPases of the Rho family (Rac and RhoA) that affect the actin cytoskeleton (33, 34), ERM proteins (ezrin-radixin-moesin) that mediate binding with the cytoskeleton, and PKC (35), which regulates the function of a wide range of proteins and intracellular signaling. Obviously, tetraspanin CD9 plays a complex role both in physiological conditions as well as in many diseases including cancer (Figure 1B).
2 Physiological roles of CD9
CD9 is a key regulator of cell adhesion in the immune system and plays an important role in the physiology of leukocytes and endothelial cells as well as in hematopoiesis and blood coagulation. Other physiological processes with the important role of CD9 include sperm-egg fusion (36), neurite outgrowth (37) or myotube formation (38). Recently, CD9 and tetraspanin 4 were revealed as membrane curvature sensors which play an essential role in the formation of migrasome and fertilization (39). In this sense, it was also shown that the reversed cone-like molecular shape of CD9 generates membrane curvature in the crystalline lipid layers, which explains the CD9 localization in regions with high membrane curvature and its implications in membrane remodeling (40). CD9 is also an exosomal marker and may affect the cellular exosomal transport and interactions between tumor cells and the stromal microenvironment (see chapter below).
One of the important functions of CD9 is the regulation of hematopoietic stem cell differentiation in the bone marrow and critical hematopoiesis events. CD9 is essential in megakaryocytic (41), lymphoid and myeloid differentiation (42). In vitro work proved that immature CD34+ bone marrow cells express high levels of CD9, while differentiated cells lose their expression (41). Also, CD9-expressing stromal cells of bone marrow affect hematopoietic cells and may be one factor that determines the degree of stem cell differentiation (43). Next, CD9 is involved in the blood clotting process, because it is a component of integral membrane proteins expressed on the cell surface and granular membranes of thrombocytes, which play an essential role in the coagulation process. It is part of an alpha 2b/beta 3 - CD9 - CD63 integrin - tetraspanin complex in activated platelets (44, 45).
The role of CD9 in different immune cells and its relevance to inflammation has recently been reviewed by Brosseau et al. (2). For example, the tetraspanin CD9 plays an important role in the immune synapse in two ways:/1/Through its association with LFA-1 on the T cell, CD9 controls the state of aggregation and adhesive capacity of this integrin./2/On the surface of the antigen-presenting cells, CD9 recruits ICAM-1 into TEMs, thus increasing its adhesive capacity (1). Its importance was also shown for the endothelial receptors such as integrin ligands ICAM-1 and VCAM-1, which facilitate leukocyte adhesion to the endothelium and their subsequent transmigration. Another important CD9 function is the inhibition of ADAM10 and ADAM17 sheddase activity, which enhances cell-cell adhesion and costimulatory capacity (1).
CD9 also affects viral (46) and bacterial infections (47, 48). Within TEMs, CD9 modulates various virus-induced processes at the membrane, including membrane fusion, viral budding and viral release. Sims et al. demonstrated that exosomes could enhance HIV-1 entry into human T and monocytic cell lines via exosomal tetraspanin proteins CD81 and CD9 (46). Infection by enveloped coronaviruses initiates with viral spike proteins binding to cellular receptors and is followed by proteolytic cleavage which prompts virus-cell membrane fusion. Infection, therefore, requires the proximity of receptors and proteases which ensures that virus-cell entry occurs at the appropriate time and place. Earnest et al. showed that CD9 is crucial for condensing these receptors and proteases (DPP4 and TMPRSS2, respectively) which allows viruses to enter cells efficiently and rapidly (49, 50). Although it might be reasonable to think that SARS-CoV-2 virulence relies on CD9 activity by clustering and scaffolding receptor and protease (i.e. ACE2 and TMPRSS2, respectively) for efficient cell entry, this hypothesis has not been validated yet in current literature (50, 51).
3 CD9 in exosomes and cell-to-cell communication
There is a growing interest in cell-cell communication mediated by secreted vesicles termed exosomes (Figure 1C) (52). Exosomes are nanoscaled extracellular vesicles (EVs) (generally, their sizes range from 30 to 150 nm) released by almost all cell types. Tetraspanins are an abundant component of exosome membranes, with CD9 being one of the most frequently found along with CD63, CD81, CD82 and TSPAN8 (53, 54). Functionally it has been demonstrated that CD9 knock-down in extracellular vesicles from breast cancer cells or recipient cells reduced endocytosis (55). Importantly, tetraspanins can influence the composition of exosomes through interactions with their binding partners. For example, a decrease in CD9 expression led to a significant reduction in the metalloprotease CD10 content in exosomes of pre-B-lymphocytes (56). CD10 can serve as a positive (57) and negative (58) prognostic factor in some cancers, but its role in exosomes has not yet been described. It has also been shown that the alteration of CD9 and CD151 on prostate cells alters the proteome of their resultant EVs and that these EVs can enhance the migratory and invasive capabilities of a non-tumorigenic prostate cellular population (59). The cargo of exosomes reflects the state of tumor cells from which they are derived. They can be explored as minimally invasive biomarkers for the early detection, diagnosis and prognosis of various cancers (16, 44, 60). Currently, there are many methods for exosome isolation and detection, ranging from classical ultracentrifugation or filtration to immunoaffinity, flow cytometry and acoustics-based microfluidic techniques (61, 62).
The mechanisms of exosome biogenesis are highly regulated through several distinct pathways, including ESCRT (endosomal sorting complexes required for transport) ‐ dependent and ESCRT‐independent pathways (17). Although the exosome release is a physiological process, its increased rate and specific cargo are favorable for oncogenic progression and metastases (16). Regarding CD9, its alterations affect extracellular vesicle secretion and mitophagy in melanoma cells (63). The exosome‐mediated communication is not limited to the cancer cells, it has also been shown in different cell types within the tumor microenvironment locally and distantly. Bioactive molecules, including CD9 in exosomes derived from cancer and stromal cells, provide the essential signals for the re-education of various cells and remodeling the tumor architecture (14, 15). For instance, in pancreatic ductal adenocarcinoma, CD9 mediated EV uptake from cancer-associated fibroblasts that promoted tumor development (15). In the model of colon cancer blocking EV-derived CD9 by antibody prevented the morphological transformation and migratory phenotype of cancer cells that uptake EVs (64). The CD9-positive EVs were higher in patients with prostate cancer compared to ones with benign prostate hyperplasia, and its secretion can be modulated in response to dihydrotestosterone. Importantly, siRNA knockdown of endogenous CD9 reduced cellular proliferation and expression of AR and prostate-specific antigen. However, knockdown of AR did not alter CD9 expression, implicating CD9 as an upstream regulator of AR (65). The exosomes may also determine organotropism and prepare the pre-metastatic niche in the sense of Stephen Paget´s seed and soil hypothesis (17, 66). Cancer cells from primary tumors release oncogenic biomolecules to the distant site before the cell invasion occurs, forming a pre-metastatic niche in the target organ that promotes successful metastatic outgrowth (16–20).
Therapy resistance in cancer can also occur via exosomes in several ways (17). Corcoran et al. reported the transfer of MDR1 by exosomes which enhanced a docetaxel efflux out of the recipient cells (67). Exosomes from drug-resistant breast cancer cells could also transmit chemoresistance do adriamycin and docetaxel by a horizontal transfer of microRNAs (68). Aung et al. have shown that tumor‐derived exosomes can protect cancer cells by transporting an abundance of proteins targeted by drugs, hence neutralising the therapy effects (23). Similarly, cells of the tumor microenvironment also release exosomes that can enhance drug resistance in cancer cells. For example, fibroblast‐derived exosomes have been shown to decrease the efficiency of chemotherapy and radiation in cancer by activating STAT1 and NOTCH3 signaling, which resulted in the expansion of therapy-resistant tumor-initiating cells (69). Chemotherapeutic drugs may also be excreted from cancer cells via exosomes (21, 22). Together, these studies described various mechanisms of exosome‐mediated drug resistance either through pumping anticancer drugs out of cells or transferring molecular cargo between cells.
4 CD9 in cancer cells: Dr. Jekyll and Mr. Hyde
CD9 expression is deregulated in a number of pathologies, including cancer, but the precise mechanism underlying these changes and the associated consequences are not fully understood (4). Bioinformatic analysis of binding sites in the promoter/enhancer region of the CD9 gene identified E2F, NFkB, SP1 and STAT3 as top transcription factors often associated with both the process of carcinogenesis and disease prognosis (70). Nevertheless, the CD9 protein plays a dual role in cancer progression, exhibiting both tumor-supportive and tumor-suppressive properties that are context-dependent.
4.1 Tumor-promoting properties
The plasma membrane protrusions enable the spreading of neoplastic cells, helping them to move between and invade surrounding stromal cells. In addition to passing through intercellular gap junctions, the neoplastic cell can also use a transcellular route for intra/extravasation, which are the essential steps of the metastatic process (71). Overexpression of CD9 has been shown to enhance FAK phosphorylation and reorganisation of the cortical actin cytoskeleton in fibrosarcoma HT1080 cells plated on laminin (5). This was also associated with the induction of MMP2 and PI3K-dependent signaling (6). Aggressive triple-negative breast cancer MDA-MB-231 cells displayed significant alterations of their plasma membrane protrusions after CD9 knockdown and had reduced tumorigenic and metastatic capacity in mouse xenografts (72). The potential role of CD9 in metastasis was indicated in a different study, describing increased expression of CD9 in breast cancer bone metastasis compared to primary tumors, where CD9 antibody treatment in vivo moderately inhibited the progression of bone lesions (73). In this sense, CD9 expression and migration were induced by native type IV collagen through a DDR1-dependent pathway in the breast cancer model, but not in non-tumorigenic MCF10A and MCF12A cells (66). Surprisingly, along with the plasma membrane, CD9 can also localize in nuclei and its depletion led to polynucleation and multipolar mitosis (74).
CD9 has also been shown to interact with VEGFR3 signaling. After intrathoracic implantation of lung cancer cells, metastasis to lymph nodes was diminished and accompanied by decreased neoangiogenesis and lymphangiogenesis in CD9 knock-out mice (12). Knocking down CD9 in human lymphatic endothelial cells also decreased their migration, proliferation and tube formation which was associated with attenuated VEGFR3 signaling. Importantly, active redistribution of endothelial CD9 was also observed during interactions between melanoma and endothelial cells in an intravasation assay (13). Anti-CD9 monoclonal antibodies specifically inhibited the transendothelial migration of melanoma cells. Association of CD9 with transendothelial invasion has also been observed by immunohistochemistry in cervical cancer as well as in melanomas (75, 76). Similarly, Hori et al. found CD9 expression at severe vessel invasion in gastric cancer (77). CD9 upregulation was also detected in ovarian carcinomas by expression profiling and immunohistochemistry (7). The CD9 upregulation associated with enhanced expression of TNF-alpha and NFkB signaling and treatment with CD9 blocking antibody ALB6 resulted in reduced tumor growth in-vivo (7). CD9 can also attenuate EGF signaling pathways in gastrointestinal cancer cells by colocalizing with EGFR (8).
One of the key drivers of tumor progression are cancer stem cells (CSCs) capable to self-differentiate, self-renew and fueling tumor growth. It has been reported that CD9 identifies a subpopulation of pancreatic cancer stem cells (CSCs) able to initiate and sustain pancreatic cancer growth as demonstrated in CD9 deficient organoid and mice models (78). Mechanistically, CD9 promoted the plasma membrane localisation of the glutamine transporter ASCT2, enhancing glutamine uptake in cancer cells. CD9 has been identified as a marker of CSCs also in the glioblastoma model, where its disruption led to decreased cell proliferation, invasion, and inhibition of tumor growth (79, 80). Decreased cell migration was also reported in highly metastatic hepatocellular carcinoma cells upon CD9 silencing (81) or in breast cancer cells using CD9-binding peptide (82). The same group successfully reduced melanoma lung metastasis after peptide binding to tetraspanin CD9. The CD9-binding peptide impeded tetraspanin web formation, cancer cell invasion and significantly reduced secretion and uptake of cancer cell exosomes (83). Antibody targeting of CD9 in pancreatic cancer disrupted CD9/ADAM interactions and led to decreased proliferation, migration and colony formation (84).
Regarding small-cell lung cancer (SCLC), CD9 was expressed preferentially in SCLC tumors and metastases from three of seven relapsed patients, whereas chemonaïve primary tumors from 16 patients were CD9 negative with only one exception (85). Mechanistically, CD9 was upregulated in chemoresistant cell lines, which adhered more tightly to fibronectin via β1 integrin, but they were less motile than the respective chemosensitive parental lines, implying a potential role of CD9 molecule in the cell adhesion-mediated drug resistance (85).
4.2 Tumor-inhibiting properties
Regarding breast cancer, Remsik et al. observed the downregulation of CD9 in cancer cells that underwent epithelial-mesenchymal transition (EMT) both in vitro and in vivo (11). High CD9 expression is associated with epithelial phenotype and favorable prognosis regarding recurrence-free survival (11). However, further mechanistic studies will be needed to clarify the role of CD9 in EMT and breast cancer progression. In ovarian cancer, the downregulation of CD9 attenuated the expression of several integrins and rearranged junctional and cytoskeletal molecules which was associated with weaker adhesion to the extracellular matrix (10). Enhanced peritoneal dissemination was observed for subclones with low CD9 expression (10), consistent with a previous report of inverse correlation of CD9 and ovarian cancer tumor stage (86). Decreased CD9 clustering may reflect the tendency of malignant cells to have less organized cell-cell junctions where tetraspanins are typically known to be clustered (3). Low affinity anti-CD9 antibody, C9BB, which binds preferentially to CD9 homodimer was used in experiments documenting a shift to heterodimers in cancer cells. This may be associated with decreased CD9 palmitoylation or altered expression of CD9 partners (3).
Takeda et al. observed a decreased lymph node metastasis of lung cancer cells transduced with CD9 without impact on the primary tumor growth (87). Similarly, ectopic expression of CD9 in fibrosarcoma cell line HT1080 reduced their lung metastatic ability by forming a complex with podoplanin, suppressing podoplanin-induced platelet aggregation (88). In line with these studies, genetic ablation of CD9 in a model of mouse prostate adenocarcinoma did not affect primary tumor development. Still, it increased the incidence of metastases to the liver but not the lungs, suggesting a possible tissue-specific manner of CD9 interactions in this model (89).
The antiproliferative effect of CD9 was also observed in in vitro model of human glioblastoma executed via inhibition of EGFR phosphorylation (9). In contrast, the downregulation of CD9 promoted cancer growth and metastasis through the upregulation of EGF in pancreatic cancer (90). In the context of SCLC that develops distant metastases extremely early, Funakoshi et al. observed the downregulation of tetraspanin CD9 in all cell lines. CD9 recovery suppressed cell motility of SCLC cells, suggesting that low expression of CD9 affects cell motility and may contribute to the highly invasive and metastatic phenotype of SCLC (91). Likewise CD9 overexpression in hepatocellular carcinoma inhibited proliferation in vitro and in vivo while CD9 knockdown enhanced in vivo growth (92).
5 Prognostic value of CD9 in solid tumors and a problem of different antibodies
Besides studies dealing with the molecular function of CD9, expression of this gene was also monitored in large cancer patient cohorts concerning tumor aggressiveness and survival. Relevant articles since 1993 are summarized in Table 1 and some are briefly commented on below. High expression of CD9 is mostly associated with good patient outcomes, with a few exceptions. These might be attributed to special cancer subtypes and different antibodies used for CD9 staining.
Table 1
| Authors | Tumor Type | Patients | Detection method | Antibody clone | Source | Therapy | Clinical outcome with high CD9 |
|---|---|---|---|---|---|---|---|
| Miyake et al., 1995 (93) | breast ca | 143 | IHC, RT-PCR, western blotting | m31-15 | in-house | S | less aggressive disease |
| Arihiro et al., 1998 (94) | breast ca | 93 | IHC, western blotting | n.s. | Dako | S | good prognosis, low risk of LN metastases |
| Houle et al., 2002 (86) | ovarian ca | 40 | IHC | m31-15 | in-house, Dr. Miyake | S/AC | less aggressive disease |
| Sauer et al., 2003 (75) | cervical ca | 44 | IHC | 72F6 | Novocastra | S | good prognosis |
| Miyamoto et al., 2001 (95) | endometrial ca | 71 | IHC | TP82 | Temecula, CA | S | good prognosis |
| Wang et al., 2007 (27) | prostatic ca | 167 | IHC | 72F6 | Novocastra | S | less aggressive disease |
| Mhawech et al., 2003 (96) | urothelial blader ca | 320 | IHC | n.s. | Novocastra | TURBT | good prognosis |
| Ai et al., 2007 (97) | urothelial blader ca | 52 | IHC | n.s. | Jingmei Biotech | TURBT | good prognosis |
| Buim et al., 2010 (98) | oral squamous ca | 179 | IHC, RT-PCR | n.s. | Neomarkers | S | good prognosis |
| Kusukawa et al., 2001 (99) | oral squamous ca | 78 | IHC, western blotting | clone 007 | in-house | S | good prognosis |
| Uchida et al., 1999 (100) | esophageal squamous ca | 108 | IHC | m31-15 | in-house | S | good prognosis |
| Zou et al., 2012 (101) | ca of gallblader | 108 | IHC | n.s. | Dako | S | good prognosis |
| Khushman et al., 2019 (102) | pancreatic ca | 29 | IHC | n.s. | Abcam | S | less aggressive disease |
| Kim et al., 2016 (103) | colorectal ca | 305 | IHC | EPR2949 | Abcam | S/AC | good prognosis in left-side tumors only |
| Hashida et al. 2003 (104) | colorectal ca | 146 | IHC, RT-PCR | m31-15 | in-house | S | good prognosis |
| Amatya et al., 2013 (105) | mesothelioma | 112 | IHC | 72F6 | Novus Biologicals | S/AC/RT | good prognosis |
| Si et Hersey 1993 (106) | melanoma | 55 | IHC | FMC56 | in-house, Dr. Zola | S | less aggressive disease |
| Woegerbauer et al., 2010 (107) | Merkell cell ca | 25 | IHC, RT-PCR, western blotting | RDI-MCD9 | Fitzgerald | S/AC/RT | good prognosis |
| Kohmo et al., 2010 (85) | small cell lung ca | 24 | IHC, RT-PCR, western blotting, flow cytometry | 72F6 | Novocastra | AC | good prognosis |
| Adachi et al., 1998 (108) | non small lung ca | 172 | IHC, RT-PCR | m31-15 | in house | S | good prognosis |
| Higashiyama et al., 1995 (109) | adenoca of lung | 132 | IHC, RT-PCR | m31-15 | in house | S | good prognosis |
(A) Summary of immunohistochemical studies – high CD9 expression associates with good clinical outcome.
AC, adjuvant chemotherapy; ca, carcinoma; IHC, immunohistochemitry; LN, lymph node; NAC, neoadjuvant chemotherapy; n.s. not specified; RT, radiotherapy; S, surgery; TURBT; transuretral resection of bladder tumor.
Discordant findings have been reported for breast, ovarian, melanoma, pancreatic and esophageal cancer. The good prognostic value of high CD9 expression was described in studies using the in-house mouse monoclonal antibody m31-15 (93, 100) and a monoclonal antibody from Dako (94). Of note, studies using the antibody clone m31-15 consistently report the good prognostic value of high CD9 in all cancer types (see Tables 1A, 1B). On the other hand, other groups reported poor outcomes for breast and ovarian cancer patients with high CD9 expression using Abcam monoclonal antibody EPR2949 or an antibody from Millipore (7, 113, 114). Kwon et al. also evaluated stromal immune cells and their CD9 expression was associated with good patient outcome (113). The same group used the EPR2949 antibody also for colorectal cancer where the high CD9 expression in tumors was associated with a good prognosis (103). Regarding stroma, high stromal CD9 evaluated with antibody clone C-4 was also associated with better survival of patients with pancreatic ductal adenocarcinoma, while positive tumor CD9 showed opposite results (115).
Table 1
| Authors | Tumor Type | Patients | Detection method | Antibody clone | Source | Therapy | Clinical outcome with high CD9 |
|---|---|---|---|---|---|---|---|
| Kim et al., 2019 (110) | papillary thyroid ca | 553 | IHC | n.s. | Novocastra | S | associated with LN metastases |
| Hori et al., 2004 (77) | gastric ca | 78 | IHC, nothern and western blotting | 72F6 and 007 | Novocastra and Dr. Mekada, resp. | S/AC | associated with advanced disease |
| Soyuer et al., 2010 (111) | gastric ca | 49 | IHC | 72F6 | Novocastra | S/AC | poor prognosis |
| Miki et al., 2018 (14) | gastric ca | 619 | IHC | n.s. | Life Technologies | S | poor prognosis, in particular of the scirrhous type |
| Huan et al., 2015 (112) | esophageal squamous ca | 104 | IHC, western blotting | n.s. | Santa Cruz | S | poor prognosis, associated with advanced disease |
| Kwon et al., 2017 (113) | breast ca | 1349 | IHC | EPR2949 | Abcam | S/AC | poor prognosis in luminal A subtype |
| Baek et al., 2019 (114) | lobular breast ca | 113 | IHC | EPR2949 | Abcam | S/AC/RT | poor prognosis |
| Hwang et al.2012 (7) | ovarian ca | 30 | IHC, microarray, RT-PCR, western blotting | n.s. | Millipore | S | associated with advanced disease |
| Lucarini et al., 2022 (76) | cutaneous melanoma | 120 | IHC | 72F6 | Novocastra | S | poor prognosis, associated with LN metastases |
| Han et al., 2022 (115) | pancreatic ca, NAC | 179 | IHC | C-4 | Santa Cruz | NAC/S | poor prognosis |
(B) Summary of immunohistochemical studies – high CD9 expression associates with poor clinical outcome.
AC, adjuvant chemotherapy; ca, carcinoma; IHC, immunohistochemitry; LN, lymph node; NAC, neoadjuvant chemotherapy; n.s. not specified; RT, radiotherapy; S, surgery; TURBT; transuretral resection of bladder tumor.
Another frequently used antibody is clone 72F6 from Novocastra. High levels of CD9 evaluated with this antibody were associated with poor prognosis in gastric cancer (111), while the association with good prognosis was found for mesothelioma, cervical and prostate cancer (75, 105, 116). Several other studies used an antibody from Novocastra without closer specification, complicating their findings’ interpretation. One of these studies investigated breast cancer samples and found no prognostic value of CD9 (117).
Overall, the interpretation of immunohistochemistry studies is problematic due to the use of different antibodies that are not thoroughly validated and essential details are missing. For example, epitopes for the most frequently used monoclonal antibodies m31-15, 72F6 and EPR2949 are unavailable. Two recent meta-analyses concluded that low CD9 expression is significantly associated with poor prognosis of cancer patients (118, 119) however, these results are oversimplified and problematic with respect to the abovementioned issues.
As described in the previous chapter, CD9 is not clearly associated with either tumor suppression or promotion. Additional mechanistic studies have recently been thoroughly reviewed by Lorico et al. They also summarized CD9 targeting with therapeutic antibodies and drew attention to the potential side effects of this strategy. This approach might further be complicated by the presence of CD9 in exosomes which may neutralize the therapeutic antibodies or enhance the pro-metastatic effects of exosomes by their enhanced endocytosis (53).
6 Conclusion
A growing body of evidence points to the important role of CD9 in various physiological processes and cancer. As highlighted in the review, CD9 is not unequivocally associated with either tumor suppression or promotion, and the antibodies used to detect CD9 might be problematic. Despite conflicting results in different types of cancer, the clinical relevance of CD9 has been highlighted by several immunohistochemical and, more importantly, mechanistic studies. Therapeutic targeting of CD9 is emerging, however, this approach may be complicated by the presence of CD9 in exosomes, which may neutralize therapeutic antibodies or enhance the pro-metastatic effects of exosomes by their increased endocytosis. In conclusion, fully validated antibodies and well-designed functional studies may help to elucidate further the role of CD9 in cancer progression and patient clinical outcome.
Statements
Author contributions
JB, SB, KS – conceptualization. RO – writing, preparation of original draft. BK, KK, KS – writing, reviewing and editing. KK - graphical figures preparation. JB - supervision, writing, reviewing and editing. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by funds from the Czech Health Research Council (grant NU21-08-00023) and the Czech Science Foundation (grant nr. 20-22984S). JB was supported by DRO (FNOL, 00098892) from the Czech Ministry of Health and by the project of National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) - Funded by the European Union - Next Generation EU.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
ReyesRCardenesBMachado-PinedaYCabanasC. Tetraspanin CD9: A key regulator of cell adhesion in the immune system. Front Immunol (2018) 9:863. doi: 10.3389/fimmu.2018.00863
2
BrosseauCColasLMagnanABrouardS. CD9 tetraspanin: A new pathway for the regulation of inflammation? Front Immunol (2018) 9:2316. doi: 10.3389/fimmu.2018.02316
3
YangXHKovalenkoOVKolesnikovaTVAndzelmMMRubinsteinEStromingerJLet al. Contrasting effects of EWI proteins, integrins, and protein palmitoylation on cell surface CD9 organization. J Biol Chem (2006) 281:12976–85. doi: 10.1074/jbc.M510617200
4
RubinsteinECharrinSTomlinsonMG. Organisation of the tetraspanin web. In: Tetraspanins. Dordrecht: Springer Netherlands (2013). p. 47–90. doi: 10.1007/978-94-007-6070-7
5
BerditchevskiFOdintsovaE. Characterization of integrin-tetraspanin adhesion complexes: Role of tetraspanins in integrin signaling. J Cell Biol (1999) 146:477–92. doi: 10.1083/jcb.146.2.477
6
SugiuraTBerditchevskiF. Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion. evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol (1999) 146:1375–89. doi: 10.1083/jcb.146.6.1375
7
HwangJRJoKLeeYSungB-JParkYWLeeJ-H. Upregulation of CD9 in ovarian cancer is related to the induction of TNF- alpha gene expression and constitutive NF-kappaB activation. Carcinogenesis (2012) 33:77–83. doi: 10.1093/carcin/bgr257
8
MurayamaYShinomuraYOritaniKMiyagawaJ-IYoshidaHNishidaMet al. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J Cell Physiol (2008) 216:135–43. doi: 10.1002/jcp.21384
9
WangG-PHanX-F. CD9 modulates proliferation of human glioblastoma cells via epidermal growth factor receptor signaling. Mol Med Rep (2015) 12:1381–6. doi: 10.3892/mmr.2015.3466
10
FuruyaMKatoHNishimuraNIshiwataIIkedaHItoRet al. Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: Morphologic alteration and reduced expression of beta1 integrin subsets. Cancer Res (2005) 65:2617–25. doi: 10.1158/0008-5472.CAN-04-3123
11
RemsikJFedrRNavratilJBinoLSlabakovaEFabianPet al. Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer. Br J Cancer (2018) 118:813–9. doi: 10.1038/bjc.2017.497
12
IwasakiTTakedaYMaruyamaKYokosakiYTsujinoKTetsumotoSet al. Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro. J Biol Chem (2013) 288:2118–31. doi: 10.1074/jbc.M112.424291
13
LongoNYáñez-MóMMittelbrunnMde la RosaGMuñozMLSánchez-MadridFet al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood (2001) 98:3717–26. doi: 10.1182/blood.v98.13.3717
14
MikiYYashiroMOkunoTKitayamaKMasudaGHirakawaKet al. CD9-positive exosomes from cancer-associated fibroblasts stimulate the migration ability of scirrhous-type gastric cancer cells. Br J Cancer (2018) 118:867–77. doi: 10.1038/bjc.2017.487
15
NigriJLecaJTubianaS-SFinettiPGuillaumondFMartinezSet al. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. Sci Signal (2022) 15:eabg8191. doi: 10.1126/scisignal.abg8191
16
RajagopalCHarikumarKB. The origin and functions of exosomes in cancer. Front Oncol (2018) 8:66. doi: 10.3389/fonc.2018.00066
17
TaiY-LChenK-CHsiehJ-TShenT-L. Exosomes in cancer development and clinical applications. Cancer Sci (2018) 109:2364–74. doi: 10.1111/cas.13697
18
PeinadoHAlečkovićMLavotshkinSMateiICosta-SilvaBMoreno-BuenoGet al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 18:883–91. doi: 10.1038/nm.2753
19
HoshinoACosta-SilvaBShenT-LRodriguesGHashimotoATesic MarkMet al. Tumour exosome integrins determine organotropic metastasis. Nature (2015) 527:329–35. doi: 10.1038/nature15756
20
Costa-SilvaBAielloNMOceanAJSinghSZhangHThakurBKet al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol (2015) 17:816–26. doi: 10.1038/ncb3169
21
SafaeiRLarsonBJChengTCGibsonMAOtaniSNaerdemannWet al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther (2005) 4:1595–604. doi: 10.1158/1535-7163.MCT-05-0102
22
JorfiSAnsa-AddoEAKholiaSStrattonDValleySLangeSet al. Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo. Sci Rep (2015) 5:13006. doi: 10.1038/srep13006
23
AungTChapuyBVogelDWenzelDOppermannMLahmannMet al. Exosomal evasion of humoral immunotherapy in aggressive b-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U.S.A. (2011) 108:15336–41. doi: 10.1073/pnas.1102855108
24
HemlerME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol (2005) 6:801–11. doi: 10.1038/nrm1736
25
SoungYHFordSZhangVChungJ. Exosomes in cancer diagnostics. Cancers (Basel) (2017) 9:8. doi: 10.3390/cancers9010008
26
RadfordKJThorneRFHerseyP. CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with beta 1 integrins in human melanoma. Biochem Biophys Res Commun (1996) 222:13–8. doi: 10.1006/bbrc.1996.0690
27
WangH-XLiQSharmaCKnoblichKHemlerME. Tetraspanin protein contributions to cancer. Biochem Soc Trans (2011) 39:547–52. doi: 10.1042/BST0390547
28
IwamotoRHigashiyamaSMitamuraTTaniguchiNKlagsbrunMMekadaE. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J (1994) 13:2322–30. doi: 10.1002/j.1460-2075.1994.tb06516.x
29
Machado-PinedaYCardenesBReyesRLopez-MartinSToribioVSanchez-OrganeroPet al. CD9 controls integrin alpha5beta1-mediated cell adhesion by modulating its association with the metalloproteinase ADAM17. Front Immunol (2018) 9:2474. doi: 10.3389/fimmu.2018.02474
30
AnzaiNLeeYYounB-SFukudaSKimY-JMantelCet al. C-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors. Blood (2002) 99:4413–21. doi: 10.1182/blood.v99.12.4413
31
HorvathGSerruVClayDBillardMBoucheixCRubinsteinE. CD19 is linked to the integrin-associated tetraspans CD9, CD81, and CD82. J Biol Chem (1998) 273:30537–43. doi: 10.1074/jbc.273.46.30537
32
Gutierrez-LopezMDGilsanzAYanez-MoMOvalleSLafuenteEMDominguezCet al. The sheddase activity of ADAM17/TACE is regulated by the tetraspanin CD9. Cell Mol Life Sci (2011) 68:3275–92. doi: 10.1007/s00018-011-0639-0
33
HerrMJMabrySEJenningsLK. Tetraspanin CD9 regulates cell contraction and actin arrangement via RhoA in human vascular smooth muscle cells. PloS One (2014) 9:e106999. doi: 10.1371/journal.pone.0106999
34
ArnaudM-PValléeARobertGBonneauJLeroyCVarin-BlankNet al. CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling. Blood (2015) 126:1802–12. doi: 10.1182/blood-2015-02-628560
35
ZhangXABontragerALHemlerME. Transmembrane-4 superfamily proteins associate with activated protein kinase c (PKC) and link PKC to specific beta(1) integrins. J Biol Chem (2001) 276:25005–13. doi: 10.1074/jbc.M102156200
36
MiyadoKYamadaGYamadaSHasuwaHNakamuraYRyuFet al. Requirement of CD9 on the egg plasma membrane for fertilization. Science (2000) 287:321–4. doi: 10.1126/science.287.5451.321
37
KagawaTMekadaEShishidoYIkenakaK. Immune system-related CD9 is expressed in mouse central nervous system myelin at a very late stage of myelination. J Neurosci Res (1997) 50:312–20. doi: 10.1002/(SICI)1097-4547(19971015)50:2<312::AID-JNR19>3.0.CO;2-9
38
CharrinSLatilMSoaveSPolesskayaAChretienFBoucheixCet al. Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81. Nat Commun (2013) 4:1674. doi: 10.1038/ncomms2675
39
DharanRGorenSCheppaliSKShendrikPBrandGVakninAet al. Transmembrane proteins tetraspanin 4 and CD9 sense membrane curvature. Proc Natl Acad Sci U.S.A. (2022) 119:e2208993119. doi: 10.1073/pnas.2208993119
40
UmedaRSatouhYTakemotoMNakada-NakuraYLiuKYokoyamaTet al. Structural insights into tetraspanin CD9 function. Nat Commun (2020) 11:1606. doi: 10.1038/s41467-020-15459-7
41
ClayDRubinsteinEMishalZAnjoAPrenantMJasminCet al. CD9 and megakaryocyte differentiation. Blood (2001) 97:1982–9. doi: 10.1182/blood.v97.7.1982
42
OritaniKWuXMedinaKHudsonJMiyakeKGimbleJMet al. Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures. Blood (1996) 87:2252–61. doi: 10.1182/blood.V87.6.2252.bloodjournal8762252
43
AoyamaKOritaniKYokotaTIshikawaJNishiuraTMiyakeKet al. Stromal cell CD9 regulates differentiation of hematopoietic stem/progenitor cells. Blood (1999) 93:2586–94. doi: 10.1182/blood.V93.8.2586
44
IsraelsSJMcMillan-WardEMEastonJRobertsonCMcNicolA. CD63 associates with the alphaIIb beta3 integrin-CD9 complex on the surface of activated platelets. Thromb Haemost (2001) 85:134–41. doi: 10.1055/s-0037-1612916
45
YunS-HSimE-HGohR-YParkJ-IHanJ-Y. Platelet activation: The mechanisms and potential biomarkers. BioMed Res Int (2016) 2016:9060143. doi: 10.1155/2016/9060143
46
SimsBFarrowALWilliamsSDBansalAKrendelchtchikovAMatthewsQL. Tetraspanin blockage reduces exosome-mediated HIV-1 entry. Arch Virol (2018) 163:1683–9. doi: 10.1007/s00705-018-3737-6
47
VentressJKPartridgeLJReadRCCozensDMacNeilSMonkPN. Peptides from tetraspanin CD9 are potent inhibitors of staphylococcus aureus adherence to keratinocytes. PloS One (2016) 11:e0160387. doi: 10.1371/journal.pone.0160387
48
GreenLRMonkPNPartridgeLJMorrisPGorringeARReadRC. Cooperative role for tetraspanins in adhesin-mediated attachment of bacterial species to human epithelial cells. Infect Immun (2011) 79:2241–9. doi: 10.1128/IAI.01354-10
49
EarnestJTHantakMPParkJ-EGallagherT. Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains. J Virol (2015) 89:6093–104. doi: 10.1128/JVI.00543-15
50
EarnestJTHantakMPLiKMcCrayPBJPerlmanSGallagherT. The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases. PloS Pathog (2017) 13:e1006546. doi: 10.1371/journal.ppat.1006546
51
PirontiGAnderssonDCLundLH. Mechanistic and therapeutic implications of extracellular vesicles as a potential link between covid-19 and cardiovascular disease manifestations. Front Cell Dev Biol (2021) 9:640723. doi: 10.3389/fcell.2021.640723
52
AndreuZYáñez-MóM. Tetraspanins in extracellular vesicle formation and function. Front Immunol (2014) 5:442. doi: 10.3389/fimmu.2014.00442
53
LoricoALorico-RappaMKarbanováJCorbeilDPizzornoG. CD9, a tetraspanin target for cancer therapy? Exp Biol Med (Maywood) (2021) 246:1121–38. doi: 10.1177/1535370220981855
54
MathivananSJiHSimpsonRJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics (2010) 73:1907–20. doi: 10.1016/j.jprot.2010.06.006
55
RappaGSantosMFGreenTMKarbanováJHasslerJBaiYet al. Nuclear transport of cancer extracellular vesicle-derived biomaterials through nuclear envelope invagination-associated late endosomes. Oncotarget (2017) 8:14443–61. doi: 10.18632/oncotarget.14804
56
MazurovDBarbashovaLFilatovA. Tetraspanin protein CD9 interacts with metalloprotease CD10 and enhances its release via exosomes. FEBS J (2013) 280:1200–13. doi: 10.1111/febs.12110
57
SmollichMGötteMYipGWYongE-SKerstingCFischgräbeJet al. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat (2007) 106:361–9. doi: 10.1007/s10549-007-9516-9
58
DeschampsLHandra-LucaAO’TooleDSauvanetARuszniewskiPBelghitiJet al. CD10 expression in pancreatic endocrine tumors: Correlation with prognostic factors and survival. Hum Pathol (2006) 37:802–8. doi: 10.1016/j.humpath.2006.02.024
59
BrzozowskiJSBondDRJankowskiHGoldieBJBurchellRNaudinCet al. Extracellular vesicles with altered tetraspanin CD9 and CD151 levels confer increased prostate cell motility and invasion. Sci Rep (2018) 8:8822. doi: 10.1038/s41598-018-27180-z
60
FigueroaJPhillipsLMShaharTHossainAGuminJKimHet al. Exosomes from glioma-associated mesenchymal stem cells increase the tumorigenicity of glioma stem-like cells via transfer of miR-1587. Cancer Res (2017) 77:5808–19. doi: 10.1158/0008-5472.CAN-16-2524
61
DongLZierenRCWangYde ReijkeTMXueWPientaKJ. Recent advances in extracellular vesicle research for urological cancers: From technology to application. Biochim Biophys Acta Rev Cancer (2019) 1871:342–60. doi: 10.1016/j.bbcan.2019.01.008
62
ShaoHImHCastroCMBreakefieldXWeisslederRLeeH. New technologies for analysis of extracellular vesicles. Chem Rev (2018) 118:1917–50. doi: 10.1021/acs.chemrev.7b00534
63
SuárezHAndreuZMazzeoCToribioVPérez-RiveraAELópez-MartínSet al. CD9 inhibition reveals a functional connection of extracellular vesicle secretion with mitophagy in melanoma cells. J Extracell Vesicles (2021) 10:e12082. doi: 10.1002/jev2.12082
64
SantosMFRappaGFontanaSKarbanováJAalamFTaiDet al. Anti-human CD9 fab fragment antibody blocks the extracellular vesicle-mediated increase in malignancy of colon cancer cells. Cells (2022) 11:2474. doi: 10.3390/cells11162474
65
SoekmadjiCRichesJDRussellPJRuelckeJEMcPhersonSWangCet al. Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Oncotarget (2017) 8:52237–55. doi: 10.18632/oncotarget.11111
66
Dos Anjos PultzBAndrés Cordero da LuzFSocorro FariaSPeixoto Ferreira de SouzaLCristina Brígido TavaresPAlonso GoulartVet al. The multifaceted role of extracellular vesicles in metastasis: Priming the soil for seeding. Int J Cancer (2017) 140:2397–407. doi: 10.1002/ijc.30595
67
CorcoranCRaniSO’BrienKO’NeillAPrencipeMSheikhRet al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PloS One (2012) 7:e50999. doi: 10.1371/journal.pone.0050999
68
ChenWLiuXLvMChenLZhaoJZhongSet al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PloS One (2014) 9:e95240. doi: 10.1371/journal.pone.0095240
69
BoelensMCWuTJNabetBYXuBQiuYYoonTet al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell (2014) 159:499–513. doi: 10.1016/j.cell.2014.09.051
70
FishilevichSNudelRRappaportNHadarRPlaschkesIIny SteinTet al. GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford) (2017) 2017:bax028. doi: 10.1093/database/bax028
71
KhuonSLiangLDettmanRWSpornPHSWysolmerskiRBChewT-L. Myosin light chain kinase mediates transcellular intravasation of breast cancer cells through the underlying endothelial cells: A three-dimensional FRET study. J Cell Sci (2010) 123:431–40. doi: 10.1242/jcs.053793
72
RappaGGreenTMKarbanováJCorbeilDLoricoA. Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells. Oncotarget (2015) 6:7970–91. doi: 10.18632/oncotarget.3419
73
KischelPBellahceneADeuxBLamourVDobsonRDE PauwEet al. Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res (2012) 32:5211–20.
74
RappaGGreenTMLoricoA. The nuclear pool of tetraspanin CD9 contributes to mitotic processes in human breast carcinoma. Mol Cancer Res (2014) 12:1840–50. doi: 10.1158/1541-7786.MCR-14-0242
75
SauerGWindischJKurzederCHeilmannVKreienbergRDeisslerH. Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res (2003) 9:6426–31.
76
LucariniGMolinelliELiciniCRizzettoGRadiGGoteriGet al. Tetraspanin CD9 expression predicts sentinel node status in patients with cutaneous melanoma. Int J Mol Sci (2022) 23:4775. doi: 10.3390/ijms23094775
77
HoriHYanoSKoufujiKTakedaJShirouzuK. CD9 expression in gastric cancer and its significance. J Surg Res (2004) 117:208–15. doi: 10.1016/j.jss.2004.01.014
78
WangVM-YFerreiraRMMAlmagroJEvanTLegraveNZaw ThinMet al. CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth. Nat Cell Biol (2019) 21:1425–35. doi: 10.1038/s41556-019-0407-1
79
ShiYZhouWChengLChenCHuangZFangXet al. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells. Cell Death Differ (2017) 24:167–80. doi: 10.1038/cdd.2016.110
80
PodergajsNMotalnHRajčevićUVerbovšekUKoršičMObadNet al. Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells. Oncotarget (2016) 7:593–609. doi: 10.18632/oncotarget.5477
81
LinQPengSYangY. Inhibition of CD9 expression reduces the metastatic capacity of human hepatocellular carcinoma cell line MHCC97-h. Int J Oncol (2018) 53:266–74. doi: 10.3892/ijo.2018.4381
82
SuwatthanarakTTanakaMMiyamotoYMiyadoKOkochiM. Inhibition of cancer-cell migration by tetraspanin CD9-binding peptide. Chem Commun (Camb) (2021) 57:4906–9. doi: 10.1039/d1cc01295a
83
SuwatthanarakTItoKTanakaMSugiuraKHoshinoAMiyamotoYet al. A peptide binding to the tetraspanin CD9 reduces cancer metastasis. Biomater Adv (2023) 146:213283. doi: 10.1016/j.bioadv.2023.213283
84
LuWFeiAJiangYChenLWangY. Tetraspanin CD9 interacts with α-secretase to enhance its oncogenic function in pancreatic cancer. Am J Transl Res (2020) 12:5525–37.
85
KohmoSKijimaTOtaniYMoriMMinamiTTakahashiRet al. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res (2010) 70:8025–35. doi: 10.1158/0008-5472.CAN-10-0996
86
HouleCDDingX-YFoleyJFAfshariCABarrettJCDavisBJ. Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol (2002) 86:69–78. doi: 10.1006/gyno.2002.6729
87
TakedaTHattoriNTokuharaTNishimuraYYokoyamaMMiyakeM. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res (2007) 67:1744–9. doi: 10.1158/0008-5472.CAN-06-3090
88
NakazawaYSatoSNaitoMKatoYMishimaKAraiHet al. Tetraspanin family member CD9 inhibits aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood (2008) 112:1730–9. doi: 10.1182/blood-2007-11-124693
89
CopelandBTBowmanMJBoucheixCAshmanLK. Knockout of the tetraspanin Cd9 in the TRAMP model of de novo prostate cancer increases spontaneous metastases in an organ-specific manner. Int J Cancer (2013) 133:1803–12. doi: 10.1002/ijc.28204
90
TangMYinGWangFLiuHZhouSNiJet al. Downregulation of CD9 promotes pancreatic cancer growth and metastasis through upregulation of epidermal growth factor on the cell surface. Oncol Rep (2015) 34:350–8. doi: 10.3892/or.2015.3960
91
FunakoshiTTachibanaIHoshidaYKimuraHTakedaYKijimaTet al. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene (2003) 22:674–87. doi: 10.1038/sj.onc.1206106
92
LiYYuSLiLChenJQuanMLiQet al. KLF4-mediated upregulation of CD9 and CD81 suppresses hepatocellular carcinoma development via JNK signaling. Cell Death Dis (2020) 11:299. doi: 10.1038/s41419-020-2479-z
93
MiyakeMNakanoKIekiYAdachiMHuangCLItoiSet al. Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res (1995) 55:4127–31.
94
ArihiroKFujiiI. Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis. Breast Cancer (1998) 5:131–8. doi: 10.1007/BF02966685
95
MiyamotoSMaruyamaAOkugawaKAkazawaKBabaHMaeharaYet al. Loss of motility-related protein 1 (MRP1/CD9) and integrin alpha3 expression in endometrial cancers. Cancer (2001) 92:542–8. doi: 10.1002/1097-0142(20010801)92:3<542::aid-cncr1353>3.0.co;2-8
96
MhawechPHerrmannFCoassinMGuillouLIselinCE. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer (2003) 98:1649–57. doi: 10.1002/cncr.11698
97
AiXZhangXWuZMaXJuZWangBet al. Expression of KAI1/CD82 and MRP-1/CD9 in transitional cell carcinoma of bladder. J Huazhong Univ Sci Technolog Med Sci (2007) 27:79–82. doi: 10.1007/s11596-007-0123-0
98
BuimMECLourencoSVCarvalhoKCCardimRPereiraCCarvalhoALet al. Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol (2010) 46:166–71. doi: 10.1016/j.oraloncology.2009.11.009
99
KusukawaJRyuFKameyamaTMekadaE. Reduced expression of CD9 in oral squamous cell carcinoma: CD9 expression inversely related to high prevalence of lymph node metastasis. J Oral Pathol Med (2001) 30:73–9. doi: 10.1034/j.1600-0714.2001.300202.x
100
UchidaSShimadaYWatanabeGLiZGHongTMiyakeMet al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer (1999) 79:1168–73. doi: 10.1038/sj.bjc.6690186
101
ZouQXiongLYangZLvFYangLMiaoX. Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder. World J Surg Oncol (2012) 10:92. doi: 10.1186/1477-7819-10-92
102
KhushmanMPatelGKLauriniJABhardwajARovedaKDonnellRet al. Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma. J Gastrointest Oncol (2019) 10:695–702. doi: 10.21037/jgo.2018.07.02
103
KimK-JKwonHJKimMCBaeYK. CD9 expression in colorectal carcinomas and its prognostic significance. J Pathol Transl Med (2016) 50:459–68. doi: 10.4132/jptm.2016.10.02
104
HashidaHTakabayashiATokuharaTHattoriNTakiTHasegawaHet al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer (2003) 89:158–67. doi: 10.1038/sj.bjc.6601015
105
AmatyaVJTakeshimaYAoeKFujimotoNOkamotoTYamadaTet al. CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma. Oncol Rep (2013) 29:21–8. doi: 10.3892/or.2012.2116
106
SiZHerseyP. Expression of the neuroglandular antigen and analogues in melanoma CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer (1993) 54:37–43. doi: 10.1002/ijc.2910540107
107
WoegerbauerMThurnherDHoubenRPammerJKloimsteinPHeiduschkaGet al. Expression of the tetraspanins CD9, CD37, CD63, and CD151 in merkel cell carcinoma: strong evidence for a posttranscriptional fine-tuning of CD9 gene expression. Mod Pathol (2010) 23:751–62. doi: 10.1038/modpathol.2009.192
108
AdachiMTakiTKonishiTHuangCIHigashiyamaMMiyakeM. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol (1998) 16:1397–406. doi: 10.1200/JCO.1998.16.4.1397
109
HigashiyamaMTakiTIekiYAdachiMHuangCLKohTet al. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res (1995) 55:6040–4. doi: 10.1002/cncr.11698
110
KimTKimYKwonHJ. Expression of CD9 and CD82 in papillary thyroid microcarcinoma and its prognostic significance. Endokrynol Pol (2019) 70:224–31. doi: 10.5603/EP.a2019.0009
111
SoyuerSSoyuerIUnalDUcarKYildizOGOrhanO. Prognostic significance of CD9 expression in locally advanced gastric cancer treated with surgery and adjuvant chemoradiotherapy. Pathol Res Pract (2010) 206:607–10. doi: 10.1016/j.prp.2010.04.004
112
HuanJGaoYXuJShengWZhuWZhangSet al. Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2015) 8:3054–61. doi: 10.1034/j.1600-0714.2001.300202.x
113
KwonHJChoiJEKangSHSonYBaeYK. Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma. Histopathology (2017) 70:1155–65. doi: 10.1111/his.13184
114
BaekJJangNChoiJEKimJ-RBaeYK. CD9 expression in tumor cells is associated with poor prognosis in patients with invasive lobular carcinoma. J Breast Cancer (2019) 22:77–85. doi: 10.4048/jbc.2019.22.e9
115
HanXZhangW-HGaoH-LLiT-JXuH-XLiHet al. Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer. J Clin Lab Anal (2022) 36:e24517. doi: 10.1002/jcla.24517
116
WangJ-CBeginLRBerubeNGChevalierSAprikianAGGourdeauHet al. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin Cancer Res (2007) 13:2354–61. doi: 10.1158/1078-0432.CCR-06-1692
117
JamilFPestonDShoushaS. CD9 immunohistochemical staining of breast carcinoma: unlikely to provide useful prognostic information for routine use. Histopathology (2001) 39:572–7. doi: 10.1046/j.1365-2559.2001.01296.x
118
KohHMJangBGLeeDHHyunCL. Increased CD9 expression predicts favorable prognosis in human cancers: A systematic review and meta-analysis. Cancer Cell Int (2021) 21:472. doi: 10.1186/s12935-021-02152-y
119
ZengPSiMSunR-XChengXLiX-YChenM-B. Prognostic value of CD9 in solid tumor: A systematic review and meta-analysis. Front Oncol (2021) 11:764630. doi: 10.3389/fonc.2021.764630
Summary
Keywords
CD9, cancer, immunohistochemistry, prognosis, exosomes
Citation
Ondruššek R, Kvokačková B, Kryštofová K, Brychtová S, Souček K and Bouchal J (2023) Prognostic value and multifaceted roles of tetraspanin CD9 in cancer. Front. Oncol. 13:1140738. doi: 10.3389/fonc.2023.1140738
Received
09 January 2023
Accepted
27 February 2023
Published
17 March 2023
Volume
13 - 2023
Edited by
Xiuwei Yang, University of Kentucky, United States
Reviewed by
Yingjun Ding, University of Oklahoma Health Sciences Center, United States
Updates
Copyright
© 2023 Ondruššek, Kvokačková, Kryštofová, Brychtová, Souček and Bouchal.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jan Bouchal, jan.bouchal@upol.cz
†Deceased
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.